Review: Baseline Gut Microbiota May Predict Immunotherapy Responses

July 28th 2021, 5:00pm


Review findings outline the gut microbiome's potential impact on immunotherapy responses.

Immunotherapy Tops Chemotherapy for Improving Outcomes in Real-World Study of Merkel Cell Carcinoma

July 23rd 2021, 2:45pm


Compared with chemotherapy, patients receiving avelumab or another immunotherapy had higher response rates and higher rates of survival in locally advanced Merkel cell carcinoma (laMCC) and metastatic Merkel cell carcinoma (mMCC).

Researchers Identify Immune Subtypes of EC, Highlighting Diversity of the Immune Microenvironment

July 17th 2021, 8:15pm


The researchers identified 3 immune subtypes of esophageal cancer (EC) among the samples, all of which had different prognostic implications.

Researchers Outline Ongoing Studies, Challenges of CAR T-cell Therapy in GBM

July 16th 2021, 6:44pm


Although there is hope chimeric antigen receptor (CAR) T-cell therapy can revolutionize how to treat glioblastoma multiforme (GBM), there is still more research to be done, say investigators, noting that research on CAR T-cell therapy in this setting is still in early stages.

Preclinical Research Sets the Stage for Potential of CAR-NK Cell Therapy in Hematologic Malignancies

July 9th 2021, 8:00pm


However, researchers also noted that similar to chimeric antigen receptor (CAR) T-cell therapy, CAR-NK cell treatment comes with its own set of challenges.

Pooled Results From Atezolizumab Trials Show Immune-Related AEs Can Predict Longer OS

July 5th 2021, 4:00pm


Data from IMpower 130, IMpower 132, and IMpower 150 confirm that combining atezolizumab with chemotherapy is the best first-line treatment in advanced NSCLC when anti-PD-L1 therapy is indicated.

ZUMA-7 Results Underscore Yescarta's Efficacy for LBCL

July 1st 2021, 4:37pm


ZUMA-7 results indicate axicabtagene ciloleucel (Yescarta) improves event-free survival among adult patients with second-line relapsed or refractory large B-cell lymphoma (LBCL).

Longer-Term Data Show Yescarta Reduces Mortality vs Other Therapies for FL

June 24th 2021, 7:11pm


Yescarta, the first and only approved chimeric antigen receptor T-cell therapy for these patients, was shown to achieve durable responses in a majority of patients and reduced the risk of death compared with other treatments.

FDA Panel Votes to Keep 4 of 6 “Dangling Approvals,” in a Sign of Things to Come

June 22nd 2021, 1:45pm


Preclinical Models Suggest Promise of CAR-NK Cell Treatment in Several Solid Tumors

June 14th 2021, 1:15pm


Previous research has suggested the efficacy of chimeric antigen receptor natural killer (CAR-NK) cells in hematological malignancies, and more recently, preclinical findings have raised the question of whether the type of treatment could be a viable, potentially more attractive option for solid tumors.